A Dual-Antigen Targeting, Hypoimmune Allogeneic CAR T to Evade Innate and Adaptive Immune Rejection and Overcome Antigen EscapeAdam Johnson, Aaron E. Foster, Brian Granger et al.|Blood|2022Cited by 2
BCMA-Targeted, Hypoimmune Allogeneic CAR T Cells Exhibit Potent Anti-Tumor Activity Together with the Ability to Evade Innate and Adaptive Immune Rejection in Pre-Clinical Tumor ModelsJeremy M. Kinder, Aaron E. Foster, Chanel Athena-Estrada et al.|Blood|2022Cited by 1